Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY accumulated deficit (Tax losses applied to a buyout)

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 19, 2024 12:33pm

167 Views

Post# 35887641

RE:RE:RE:RE:ONCY accumulated deficit (Tax losses applied to a buyout)

The basic underlying value of ONCY based simply on the company's accumulated deficit, and nothing more, is approximately US $5 per share, which indicates why analysts have a near term target of US$5 per share price, and further indicates that the stock price of ONCY is being significantly throttled by some particular player/s, such as Quentin30 and the team of operatives he identifies with

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing